RALEIGH, N.C., Oct. 30, 2023/– Contego Medical Inc., a company dedicated to improving patient outcomes and procedural efficiency in the treatment of carotid and peripheral vascular disease, today announced the completion of 1-year follow-up visits for patients in the PERFORMANCE II Carotid Stent Trial and the upcoming presentation of 30-day and 1-year results at the VIVA (Vascular InterVentional Advances) meeting.
WHO: Dr. William Gray, System Chief of the Division of Cardiovascular Diseases at Main Line Health and Co-National Principal Investigator of the PERFORMANCE II trial
WHAT: Presenting 30-day and 1-year outcome results from the PERFORMANCE II Study in a late-breaking clinical trial session
WHEN: Nov. 1, 2023, 10:45 a.m.
WHERE: VIVA, Wynn Hotel Las Vegas, Global Theater
ADDITIONAL INFORMATION: Contego Medical is also sponsoring a lunch symposium at VIVA: Revolutionizing Carotid and Peripheral Revascularization, Nov. 1 at 12:00 p.m. in Margaux 2 at the Wynn Hotel
The session will include the latest clinical data on the Neuroguard IEP Carotid Stent System and a discussion on the implications of the recent national coverage decision (NCD) for carotid artery stenting.
The lunch will be led by faculty members Drs. William Gray, Sean Lyden, Alexandros Mallios, Jay Mathews, Robert Mendes, Ken Rosenfield, and Mitch Silver.
ABOUT THE PERFORMANCE II Trial
It is a prospective multicenter trial to evaluate the safety and effectiveness of the Neuroguard IEP® System and enrolled 305 patients at 40 sites. The 1-year results will support a U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) application.
The Neuroguard IEP System leverages Contego Medical’s clinically proven integrated embolic protection (IEP) technology, a unique platform with a micro-filter integrated on the delivery catheter. It is designed to deliver added safety where it matters most – during stent placement and balloon dilation. The micro-filter with 40µm pores captures the micro-emboli other protection mechanisms don’t, giving physicians the procedural confidence that comes with advanced stroke protection in the treatment of their patients.
The high-performance closed cell stent is designed to provide radial strength and flexibility and leverages the proven long-term material performance of nitinol.
About Contego Medical, Inc.
www.contegomedical.com
Contego Medical, Inc. is the leader in developing state-of-the-art solutions that transform complex cases into simplified procedures. The company’s portfolio of integrated, multi-functional products is designed to improve patient outcomes and procedural efficiency in the treatment of carotid and peripheral vascular disease. The patented Neuroguard IEP System is currently limited by Federal US law to investigational use only in the PERFORMANCE II study (NCT04201132). More than 3,000 patients have been treated with Contego Medical products to-date.
Paladin, Neuroguard IEP, Vanguard IEP, Excipio, Integrated Embolic Protection, and FlexRing are trademarks or registered trademarks of Contego Medical.
SOURCE Contego Medical, Inc
###
